[S02DA03, antipyrine, The serum concentration of Antipyrine can be increased when it is combined with Peginterferon alfa-2b.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon alfa-2b.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Antithymocyte immunoglobulin (rabbit).]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Streptozocin.]
[M04AX02, pegloticase, The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Peginterferon alfa-2b.]
[L04AA27, fingolimod, Peginterferon alfa-2b may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Peginterferon alfa-2b.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Peginterferon alfa-2b.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be increased when combined with Peginterferon alfa-2b.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mercaptopurine.]
[N06DA01, tacrine, The serum concentration of Tacrine can be increased when it is combined with Peginterferon alfa-2b.]
[L02BA01, tamoxifen, The serum concentration of Tamoxifen can be increased when it is combined with Peginterferon alfa-2b.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Teniposide.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Peginterferon alfa-2b.]
[G03BA03, testosterone, The metabolism of Testosterone can be increased when combined with Peginterferon alfa-2b.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Peginterferon alfa-2b.]
[A04AD10, dronabinol, The metabolism of Dronabinol can be increased when combined with Peginterferon alfa-2b.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Thalidomide.]
[R03DA07, theobromine, The serum concentration of Theobromine can be increased when it is combined with Peginterferon alfa-2b.]
[R03DA04, theophylline, The serum concentration of Theophylline can be increased when it is combined with Peginterferon alfa-2b.]
[P02CA02, thiabendazole, The serum concentration of Thiabendazole can be increased when it is combined with Peginterferon alfa-2b.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tioguanine.]
[N05AC02, thioridazine, The metabolism of Thioridazine can be decreased when combined with Peginterferon alfa-2b.]
[N05AF04, thiothixene, The serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Peginterferon alfa-2b.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Peginterferon alfa-2b.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Peginterferon alfa-2b.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be increased when combined with Peginterferon alfa-2b.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be increased when combined with Peginterferon alfa-2b.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Peginterferon alfa-2b.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Peginterferon alfa-2b.]
[N06AX05, trazodone, The metabolism of Trazodone can be decreased when combined with Peginterferon alfa-2b.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Triamcinolone.]
[C03DB02, triamterene, The serum concentration of Triamterene can be increased when it is combined with Peginterferon alfa-2b.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Peginterferon alfa-2b.]
[N05AB06, trifluoperazine, The serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Trifluridine.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mometasone.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be increased when combined with Peginterferon alfa-2b.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be increased when combined with Peginterferon alfa-2b.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Peginterferon alfa-2b.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Peginterferon alfa-2b.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Belimumab.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Peginterferon alfa-2b.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Belatacept.]
[B01AF01, rivaroxaban, The risk or severity of bleeding can be increased when Rivaroxaban is combined with Peginterferon alfa-2b.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Ticagrelor is combined with Peginterferon alfa-2b.]
[C08DA01, verapamil, The serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vindesine.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon alfa-2b.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Peginterferon alfa-2b.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Zidovudine.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Peginterferon alfa-2b.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Brentuximab vedotin.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2b.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be increased when combined with Peginterferon alfa-2b.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Alemtuzumab.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Peginterferon alfa-2b.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Peginterferon alfa-2b.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Peginterferon alfa-2b.]
[C07AB03, atenolol, The metabolism of Atenolol can be decreased when combined with Peginterferon alfa-2b.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Peginterferon alfa-2b.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Rituximab.]
[J02AC03, voriconazole, The metabolism of Voriconazole can be increased when combined with Peginterferon alfa-2b.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be increased when combined with Peginterferon alfa-2b.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Peginterferon alfa-2b.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Prednylidene.]
[B03XA04, peginesatide, The therapeutic efficacy of Peginesatide can be decreased when used in combination with Peginterferon alfa-2b.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Azacitidine.]
[L04AX01, azathioprine, The serum concentration of Azathioprine can be increased when it is combined with Peginterferon alfa-2b.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gemcitabine.]
[G04BE10, avanafil, The metabolism of Avanafil can be increased when combined with Peginterferon alfa-2b.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Peginterferon alfa-2b.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gemtuzumab ozogamicin.]
[A08AA11, lorcaserin, The serum concentration of Lorcaserin can be increased when it is combined with Peginterferon alfa-2b.]
[G04BD12, mirabegron, The metabolism of Mirabegron can be decreased when combined with Peginterferon alfa-2b.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Carfilzomib.]
[L02BB04, enzalutamide, The metabolism of Enzalutamide can be increased when combined with Peginterferon alfa-2b.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Peginterferon alfa-2b.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldosterone.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Peginterferon alfa-2b.]
[N04BD02, rasagiline, The serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Peginterferon alfa-2b.]
[N03AX22, perampanel, The serum concentration of Perampanel can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA29, tofacitinib, Peginterferon alfa-2b may increase the immunosuppressive activities of Tofacitinib.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Peginterferon alfa-2b.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Peginterferon alfa-2b.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be increased when combined with Peginterferon alfa-2b.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Peginterferon alfa-2b.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Peginterferon alfa-2b.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Apixaban is combined with Peginterferon alfa-2b.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Peginterferon alfa-2b.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Peginterferon alfa-2b.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be increased when combined with Peginterferon alfa-2b.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dimethyl fumarate.]
[A06AX06, tegaserod, The metabolism of Tegaserod can be decreased when combined with Peginterferon alfa-2b.]
[R02AD01, benzocaine, The serum concentration of Benzocaine can be increased when it is combined with Peginterferon alfa-2b.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Peginterferon alfa-2b.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Everolimus.]
[N04AC01, benztropine, The metabolism of Benzatropine can be decreased when combined with Peginterferon alfa-2b.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be increased when combined with Peginterferon alfa-2b.]
[P03AX06, benzyl alcohol, The serum concentration of Benzyl alcohol can be increased when it is combined with Peginterferon alfa-2b.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Peginterferon alfa-2b.]
[C08EA02, bepridil, The metabolism of Bepridil can be decreased when combined with Peginterferon alfa-2b.]
[L03AA14, lipegfilgrastim, Peginterferon alfa-2b may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Peginterferon alfa-2b.]
[A10BK01, dapagliflozin, The serum concentration of Dapagliflozin can be increased when it is combined with Peginterferon alfa-2b.]
[C07AB04, acebutolol, The metabolism of Acebutolol can be decreased when combined with Peginterferon alfa-2b.]
[N05CH03, tasimelteon, The serum concentration of Tasimelteon can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA32, apremilast, The serum concentration of Apremilast can be increased when it is combined with Peginterferon alfa-2b.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Betamethasone.]
[S01ED02, betaxolol, The serum concentration of Betaxolol can be increased when it is combined with Peginterferon alfa-2b.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Peginterferon alfa-2b.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Siltuximab.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Vorapaxar is combined with Peginterferon alfa-2b.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Peginterferon alfa-2b.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Idelalisib.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be increased when combined with Peginterferon alfa-2b.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Peginterferon beta-1a.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Peginterferon alfa-2b.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Decitabine.]
[L04AX05, pirfenidone, The serum concentration of Pirfenidone can be increased when it is combined with Peginterferon alfa-2b.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Blinatumomab.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Peginterferon alfa-2b.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Olaparib.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be increased when combined with Peginterferon alfa-2b.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Peginterferon alfa-2b.]
[N06AX11, mirtazapine, The serum concentration of Mirtazapine can be increased when it is combined with Peginterferon alfa-2b.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Panobinostat.]
[N02BE01, acetaminophen, The serum concentration of Acetaminophen can be increased when it is combined with Peginterferon alfa-2b.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bleomycin.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Peginterferon alfa-2b.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Peginterferon alfa-2b.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Peginterferon alfa-2b.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Peginterferon alfa-2b.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be increased when combined with Peginterferon alfa-2b.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Peginterferon alfa-2b.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mepolizumab.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be increased when combined with Peginterferon alfa-2b.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be increased when combined with Peginterferon alfa-2b.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be increased when combined with Peginterferon alfa-2b.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ixekizumab.]
[N05BA08, bromazepam, The serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b.]
[N01BB01, bupivacaine, The serum concentration of Levobupivacaine can be increased when it is combined with Peginterferon alfa-2b.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be decreased when combined with Peginterferon alfa-2b.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Peginterferon alfa-2b.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Peginterferon alfa-2b.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be increased when combined with Peginterferon alfa-2b.]
[S01GX07, azelastine, The serum concentration of Azelastine can be increased when it is combined with Peginterferon alfa-2b.]
[L01XK03, rucaparib, The serum concentration of Rucaparib can be increased when it is combined with Peginterferon alfa-2b.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Brodalumab.]
[R03DA08, bamifylline, The serum concentration of Bamifylline can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ocrelizumab.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Peginterferon alfa-2b.]
[N06BC01, caffeine, The serum concentration of Caffeine can be increased when it is combined with Peginterferon alfa-2b.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daclizumab.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Linezolid.]
[J05AE09, tipranavir, The metabolism of Tipranavir can be decreased when combined with Peginterferon alfa-2b.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Peginterferon alfa-2b.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Infliximab.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Peginterferon alfa-2b.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Guselkumab.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be increased when combined with Peginterferon alfa-2b.]
[L01XX59, enasidenib, The serum concentration of Enasidenib can be increased when it is combined with Peginterferon alfa-2b.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vorinostat.]
[J05AG03, efavirenz, The serum concentration of Efavirenz can be increased when it is combined with Peginterferon alfa-2b.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Peginterferon alfa-2b.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Basiliximab.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Raltitrexed.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Peginterferon alfa-2b.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Peginterferon alfa-2b.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Peginterferon alfa-2b.]
[N01BX04, capsaicin, The serum concentration of Capsaicin can be increased when it is combined with Peginterferon alfa-2b.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Carbamazepine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Peginterferon alfa-2b.]
[C07AG02, carvedilol, The serum concentration of Carvedilol can be increased when it is combined with Peginterferon alfa-2b.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be increased when combined with Peginterferon alfa-2b.]
[A16AB19, pegvaliase, The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Peginterferon alfa-2b.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Baricitinib.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Peginterferon alfa-2b.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Peginterferon alfa-2b.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be decreased when combined with Peginterferon alfa-2b.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Peginterferon alfa-2b.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Peginterferon alfa-2b.]
[N03AX17, stiripentol, The metabolism of Peginterferon alfa-2b can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Peginterferon alfa-2b.]
[L03AX21, elapegademase, The therapeutic efficacy of Elapegademase can be decreased when used in combination with Peginterferon alfa-2b.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be increased when combined with Peginterferon alfa-2b.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be increased when combined with Peginterferon alfa-2b.]
[R03DA02, oxtriphylline, The serum concentration of Oxtriphylline can be increased when it is combined with Peginterferon alfa-2b.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Peginterferon alfa-2b.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Emapalumab.]
[L01AD01, carmustine, The serum concentration of Carmustine can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Peginterferon alfa-2b.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Peginterferon alfa-2b.]
[P02BX04, triclabendazole, The serum concentration of Triclabendazole can be increased when it is combined with Peginterferon alfa-2b.]
[N06AX27, esketamine, The metabolism of Esketamine can be increased when combined with Peginterferon alfa-2b.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Peginterferon alfa-2b.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Peginterferon alfa-2b.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cloprednol.]
[C09CA06, candesartan, The metabolism of Candesartan can be increased when combined with Peginterferon alfa-2b.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon alfa-2b.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Risankizumab.]
[M03BX08, cyclobenzaprine, The serum concentration of Cyclobenzaprine can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Upadacitinib.]
[N07XX11, pitolisant, The metabolism of Pitolisant can be decreased when combined with Peginterferon alfa-2b.]
[N04CX01, istradefylline, The serum concentration of Istradefylline can be increased when it is combined with Peginterferon alfa-2b.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Peginterferon alfa-2b.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Peginterferon alfa-2b.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Deflazacort.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Trastuzumab emtansine.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Peginterferon alfa-2b.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Diroximel fumarate.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Peginterferon alfa-2b.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be increased when combined with Peginterferon alfa-2b.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Peginterferon alfa-2b.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be increased when combined with Peginterferon alfa-2b.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Teprotumumab.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Peginterferon alfa-2b.]
[N02CC07, frovatriptan, The serum concentration of Frovatriptan can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ozanimod.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Peginterferon alfa-2b.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Peginterferon alfa-2b.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Peginterferon alfa-2b.]
[M01AH02, rofecoxib, The serum concentration of Rofecoxib can be increased when it is combined with Peginterferon alfa-2b.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Peginterferon alfa-2b.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Chloramphenicol.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluprednidene.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2b.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Peginterferon alfa-2b is combined with Inebilizumab.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Stepronin.]
[P01BB01, proguanil, The metabolism of Proguanil can be increased when combined with Peginterferon alfa-2b.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Satralizumab.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be decreased when combined with Peginterferon alfa-2b.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Peginterferon alfa-2b.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Peginterferon alfa-2b.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Peginterferon alfa-2b.]
[N05AA01, chlorpromazine, The serum concentration of Chlorpromazine can be increased when it is combined with Peginterferon alfa-2b.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be increased when combined with Peginterferon alfa-2b.]
[M03BB03, chlorzoxazone, The serum concentration of Chlorzoxazone can be increased when it is combined with Peginterferon alfa-2b.]
[M01AB08, etodolac, The metabolism of Etodolac can be increased when combined with Peginterferon alfa-2b.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be increased when combined with Peginterferon alfa-2b.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fludarabine.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Voclosporin.]
[N06BA10, fenethylline, The serum concentration of Fenethylline can be increased when it is combined with Peginterferon alfa-2b.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Flunisolide.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Peginterferon alfa-2b.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ponesimod.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be decreased when combined with Peginterferon alfa-2b.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluocinolone acetonide.]
[N07CA02, cinnarizine, The serum concentration of Cinnarizine can be increased when it is combined with Peginterferon alfa-2b.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cisplatin.]
[N06AB04, citalopram, The metabolism of Citalopram can be decreased when combined with Peginterferon alfa-2b.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Belumosudil.]
[P01CA03, fexinidazole, The serum concentration of Fexinidazole can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Anifrolumab.]
[M01AG01, mefenamic acid, The serum concentration of Mefenamic acid can be increased when it is combined with Peginterferon alfa-2b.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be increased when combined with Peginterferon alfa-2b.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be increased when combined with Peginterferon alfa-2b.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be increased when combined with Peginterferon alfa-2b.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Peginterferon alfa-2b.]
[N01BB10, levobupivacaine, The serum concentration of Levobupivacaine can be increased when it is combined with Peginterferon alfa-2b.]
[N06AA04, clomipramine, The serum concentration of Clomipramine can be increased when it is combined with Peginterferon alfa-2b.]
[S01EA04, clonidine, The serum concentration of Clonidine can be increased when it is combined with Peginterferon alfa-2b.]
[C01EB24, mavacamten, The metabolism of Mavacamten can be increased when combined with Peginterferon alfa-2b.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Deucravacitinib.]
[A04AA01, ondansetron, The serum concentration of Ondansetron can be increased when it is combined with Peginterferon alfa-2b.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Peginterferon alfa-2b is combined with Clozapine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Peginterferon alfa-2b.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Leflunomide.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Peginterferon alfa-2b.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Nelarabine.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Peginterferon alfa-2b.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be increased when combined with Peginterferon alfa-2b.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Peginterferon alfa-2b.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Peginterferon alfa-2b.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be increased when combined with Peginterferon alfa-2b.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Peginterferon alfa-2b.]
[S01AD03, acyclovir, The serum concentration of Acyclovir can be increased when it is combined with Peginterferon alfa-2b.]
[L01EA01, imatinib, The serum concentration of Imatinib can be increased when it is combined with Peginterferon alfa-2b.]
[N07BC04, lofexidine, The serum concentration of Lofexidine can be increased when it is combined with Peginterferon alfa-2b.]
[S01AE04, lomefloxacin, The serum concentration of Lomefloxacin can be increased when it is combined with Peginterferon alfa-2b.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Peginterferon alfa-2b.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Peginterferon alfa-2b.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Alefacept.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Peginterferon alfa-2b.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Peginterferon alfa-2b.]
[N06AX07, minaprine, The metabolism of Minaprine can be decreased when combined with Peginterferon alfa-2b.]
[S01XA18, cyclosporine, Peginterferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Moclobemide can be decreased when combined with Peginterferon alfa-2b.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be increased when combined with Peginterferon alfa-2b.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cytarabine.]
[J05AF10, entecavir, The serum concentration of Entecavir can be increased when it is combined with Peginterferon alfa-2b.]
[M01AH05, etoricoxib, The serum concentration of Etoricoxib can be increased when it is combined with Peginterferon alfa-2b.]
[L01AX04, dacarbazine, The serum concentration of Dacarbazine can be increased when it is combined with Peginterferon alfa-2b.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dactinomycin.]
[J04BA02, dapsone, The metabolism of Dapsone can be increased when combined with Peginterferon alfa-2b.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daunorubicin.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Peginterferon alfa-2b.]
[A04AD11, nabilone, The metabolism of Nabilone can be increased when combined with Peginterferon alfa-2b.]
[M01AX01, nabumetone, The serum concentration of Nabumetone can be increased when it is combined with Peginterferon alfa-2b.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Peginterferon alfa-2b.]
[N06AX06, nefazodone, The metabolism of Nefazodone can be decreased when combined with Peginterferon alfa-2b.]
[C01CA23, theodrenaline, The serum concentration of Theodrenaline can be increased when it is combined with Peginterferon alfa-2b.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Peginterferon alfa-2b.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Peginterferon alfa-2b.]
[N06AB10, escitalopram, The metabolism of Escitalopram can be decreased when combined with Peginterferon alfa-2b.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Peginterferon alfa-2b.]
[N06AA01, desipramine, The metabolism of Desipramine can be decreased when combined with Peginterferon alfa-2b.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Desoximetasone.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Oxaliplatin.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dexamethasone.]
[A08AA04, dexfenfluramine, The serum concentration of Dexfenfluramine can be increased when it is combined with Peginterferon alfa-2b.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Peginterferon alfa-2b.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be decreased when combined with Peginterferon alfa-2b.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Peginterferon alfa-2b.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be increased when combined with Peginterferon alfa-2b.]
[N06AB05, paroxetine, The serum concentration of Paroxetine can be increased when it is combined with Peginterferon alfa-2b.]
[B01AC04, clopidogrel, The serum concentration of Clopidogrel can be increased when it is combined with Peginterferon alfa-2b.]
[C04AD01, pentifylline, The serum concentration of Pentifylline can be increased when it is combined with Peginterferon alfa-2b.]
[N05BA01, diazepam, The metabolism of Diazepam can be increased when combined with Peginterferon alfa-2b.]
[S01BC03, diclofenac, The serum concentration of Diclofenac can be increased when it is combined with Peginterferon alfa-2b.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ixabepilone.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be increased when it is combined with Peginterferon alfa-2b.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pirarubicin.]
[L03AA13, pegfilgrastim, The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegfilgrastim.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Difluocortolone.]
[C02DB01, dihydralazine, The serum concentration of Dihydralazine can be increased when it is combined with Peginterferon alfa-2b.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pegaspargase.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be increased when combined with Peginterferon alfa-2b.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Lenalidomide.]
[J05AE08, atazanavir, The metabolism of Atazanavir can be increased when combined with Peginterferon alfa-2b.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be increased when combined with Peginterferon alfa-2b.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Peginterferon alfa-2b.]
[N06BC02, propentofylline, The serum concentration of Propentofylline can be increased when it is combined with Peginterferon alfa-2b.]
[R03DA03, proxyphylline, The serum concentration of Proxyphylline can be increased when it is combined with Peginterferon alfa-2b.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Peginterferon alfa-2b.]
[N05CD10, quazepam, The metabolism of Quazepam can be increased when combined with Peginterferon alfa-2b.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Peginterferon alfa-2b.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon alfa-2b.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sirolimus.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be decreased when combined with Peginterferon alfa-2b.]
[C01BA03, disopyramide, The serum concentration of Disopyramide can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Natalizumab.]
[N07XX02, riluzole, The serum concentration of Riluzole can be increased when it is combined with Peginterferon alfa-2b.]
[N05AX08, risperidone, The metabolism of Risperidone can be decreased when combined with Peginterferon alfa-2b.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Efalizumab.]
[N01BB09, ropivacaine, The serum concentration of Ropivacaine can be increased when it is combined with Peginterferon alfa-2b.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sunitinib.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Peginterferon alfa-2b.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be increased when combined with Peginterferon alfa-2b.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be decreased when combined with Peginterferon alfa-2b.]
[A03FA03, domperidone, The serum concentration of Domperidone can be increased when it is combined with Peginterferon alfa-2b.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Peginterferon alfa-2b.]
[N06AA12, doxepin, The serum concentration of Doxepin can be increased when it is combined with Peginterferon alfa-2b.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Doxorubicin.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Peginterferon alfa-2b.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Peginterferon alfa-2b.]
[R03DA01, dyphylline, The metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2b.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Peginterferon alfa-2b.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Corticotropin.]
[J01MA05, temafloxacin, The serum concentration of Temafloxacin can be increased when it is combined with Peginterferon alfa-2b.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Temozolomide.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be increased when combined with Peginterferon alfa-2b.]
[D01BA02, terbinafine, The serum concentration of Terbinafine can be increased when it is combined with Peginterferon alfa-2b.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Peginterferon alfa-2b.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Peginterferon alfa-2b.]
[C03CA04, torsemide, The metabolism of Torasemide can be increased when combined with Peginterferon alfa-2b.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Peginterferon alfa-2b.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Peginterferon alfa-2b.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vinorelbine.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Peginterferon alfa-2b.]
[N06AX16, venlafaxine, The metabolism of Venlafaxine can be decreased when combined with Peginterferon alfa-2b.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Epirubicin.]
[N05CF02, zolpidem, The serum concentration of Zolpidem can be increased when it is combined with Peginterferon alfa-2b.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be increased when combined with Peginterferon alfa-2b.]
[N05AX11, zotepine, The serum concentration of Zotepine can be increased when it is combined with Peginterferon alfa-2b.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Peginterferon alfa-2b.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Carboplatin.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Peginterferon alfa-2b.]
[H05BX01, cinacalcet, The serum concentration of Cinacalcet can be increased when it is combined with Peginterferon alfa-2b.]
[G03CA03, estradiol, The serum concentration of Estradiol can be increased when it is combined with Peginterferon alfa-2b.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Estramustine.]
[G03CA57, estrogens, conjugated (USP), The serum concentration of Conjugated estrogens can be increased when it is combined with Peginterferon alfa-2b.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Peginterferon alfa-2b.]
[L02AA03, ethinyl estradiol, The serum concentration of Ethinylestradiol can be increased when it is combined with Peginterferon alfa-2b.]
[M01AC06, meloxicam, The metabolism of Meloxicam can be increased when combined with Peginterferon alfa-2b.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Peginterferon alfa-2b.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Peginterferon alfa-2b.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Peginterferon alfa-2b.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Peginterferon alfa-2b.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Peginterferon alfa-2b.]
[R06AX12, terfenadine, The metabolism of Terfenadine can be decreased when combined with Peginterferon alfa-2b.]
[N06AX12, bupropion, The metabolism of Bupropion can be increased when combined with Peginterferon alfa-2b.]
[N06AB08, fluvoxamine, The serum concentration of Fluvoxamine can be increased when it is combined with Peginterferon alfa-2b.]
[C01BB03, tocainide, The serum concentration of Tocainide can be increased when it is combined with Peginterferon alfa-2b.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Peginterferon alfa-2b.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Muromonab.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Peginterferon alfa-2b.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dexrazoxane.]
[P02CA03, albendazole, The serum concentration of Albendazole can be increased when it is combined with Peginterferon alfa-2b.]
[N03AX26, fenfluramine, The serum concentration of Fenfluramine can be increased when it is combined with Peginterferon alfa-2b.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Peginterferon alfa-2b.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cladribine.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Peginterferon alfa-2b.]
[C01BC04, flecainide, The serum concentration of Flecainide can be increased when it is combined with Peginterferon alfa-2b.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fludrocortisone.]
[N07CA03, flunarizine, The serum concentration of Flunarizine can be increased when it is combined with Peginterferon alfa-2b.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be increased when combined with Peginterferon alfa-2b.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluocinonide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluocortolone.]
[V03AZ01, ethanol, The serum concentration of Ethanol can be increased when it is combined with Peginterferon alfa-2b.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Floxuridine.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluorometholone.]
[L01BC02, fluorouracil, The serum concentration of Fluorouracil can be increased when it is combined with Peginterferon alfa-2b.]
[N06AB03, fluoxetine, The serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Peginterferon alfa-2b.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be increased when combined with Peginterferon alfa-2b.]
[L02BB01, flutamide, The serum concentration of Flutamide can be increased when it is combined with Peginterferon alfa-2b.]
[L01BC03, tegafur, The serum concentration of Tegafur can be increased when it is combined with Peginterferon alfa-2b.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Peginterferon alfa-2b.]
[J05AF11, telbivudine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Telbivudine.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.]
[C01CA21, cafedrine, The serum concentration of Cafedrine can be increased when it is combined with Peginterferon alfa-2b.]
[J05AG04, etravirine, The metabolism of Etravirine can be increased when combined with Peginterferon alfa-2b.]
[A10BB01, glyburide, The metabolism of Glyburide can be increased when combined with Peginterferon alfa-2b.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be increased when combined with Peginterferon alfa-2b.]
[A10BB07, glipizide, The metabolism of Glipizide can be increased when combined with Peginterferon alfa-2b.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Peginterferon alfa-2b.]
[L01EX02, sorafenib, The serum concentration of Sorafenib can be increased when it is combined with Peginterferon alfa-2b.]
[C07AB09, esmolol, The metabolism of Esmolol can be decreased when combined with Peginterferon alfa-2b.]
[S01LA03, pegaptanib, The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Peginterferon alfa-2b.]
[B01AA12, fluindione, The metabolism of Fluindione can be increased when combined with Peginterferon alfa-2b.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Peginterferon alfa-2b.]
[N01AB01, halothane, The metabolism of Halothane can be increased when combined with Peginterferon alfa-2b.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be decreased when combined with Peginterferon alfa-2b.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Irinotecan.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Peginterferon alfa-2b.]
[C09CA01, losartan, The metabolism of Losartan can be increased when combined with Peginterferon alfa-2b.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Peginterferon alfa-2b.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Altretamine.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be increased when combined with Peginterferon alfa-2b.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Peginterferon alfa-2b.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Peginterferon alfa-2b.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Peginterferon alfa-2b.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Peginterferon alfa-2b.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Peginterferon alfa-2b.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hydroxyurea.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be increased when combined with Peginterferon alfa-2b.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Peginterferon alfa-2b.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ifosfamide.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Peginterferon alfa-2b.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tixocortol.]
[M03BX02, tizanidine, The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Indomethacin.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfa-2b.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Eculizumab.]
[N05CH02, ramelteon, The serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b.]
[L01XX35, anagrelide, The serum concentration of Anagrelide can be increased when it is combined with Peginterferon alfa-2b.]
[C07AA01, alprenolol, The metabolism of Alprenolol can be decreased when combined with Peginterferon alfa-2b.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfacon-1.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Peginterferon alfa-2b.]
[L03AX04, pegademase bovine, The therapeutic efficacy of Pegademase can be decreased when used in combination with Peginterferon alfa-2b.]
[J05AB13, penciclovir, The serum concentration of Penciclovir can be increased when it is combined with Peginterferon alfa-2b.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Peginterferon alfa-2b.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be increased when combined with Peginterferon alfa-2b.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Peginterferon alfa-2b.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Peginterferon alfa-2b.]
[N05AH03, olanzapine, The serum concentration of Olanzapine can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Abatacept.]
[N04BC09, rotigotine, The metabolism of Rotigotine can be decreased when combined with Peginterferon alfa-2b.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Peginterferon alfa-2b.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be increased when combined with Peginterferon alfa-2b.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mitomycin.]
[S02DA01, lidocaine, The serum concentration of Lidocaine can be increased when it is combined with Peginterferon alfa-2b.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Peginterferon alfa-2b.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Lomustine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Peginterferon alfa-2b.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Nilotinib.]
[N06AA21, maprotiline, The serum concentration of Maprotiline can be increased when it is combined with Peginterferon alfa-2b.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mechlorethamine.]
[R06AE05, meclizine, The metabolism of Meclizine can be decreased when combined with Peginterferon alfa-2b.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Peginterferon alfa-2b.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Peginterferon alfa-2b.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Peginterferon alfa-2b.]
[N05CH01, melatonin, The serum concentration of Melatonin can be increased when it is combined with Peginterferon alfa-2b.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Melphalan.]
[N03AB04, mephenytoin, The serum concentration of Mephenytoin can be increased when it is combined with Peginterferon alfa-2b.]
[N05AC03, mesoridazine, The metabolism of Mesoridazine can be decreased when combined with Peginterferon alfa-2b.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be decreased when combined with Peginterferon alfa-2b.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Peginterferon alfa-2b.]
[N07BC02, methadone, The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2b.]
[N06BA03, methamphetamine, The metabolism of Metamfetamine can be decreased when combined with Peginterferon alfa-2b.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Methimazole.]
[L01BA04, pemetrexed, The serum concentration of Pemetrexed can be increased when it is combined with Peginterferon alfa-2b.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Methotrexate.]
[N05AA02, methotrimeprazine, The metabolism of Methotrimeprazine can be decreased when combined with Peginterferon alfa-2b.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Peginterferon alfa-2b.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Peginterferon alfa-2b.]
[V04CG05, methylene blue, The serum concentration of Methylene blue can be increased when it is combined with Peginterferon alfa-2b.]
[R03DA05, aminophylline, The serum concentration of Aminophylline can be increased when it is combined with Peginterferon alfa-2b.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Methylprednisolone.]
[A03FA01, metoclopramide, The serum concentration of Metoclopramide can be increased when it is combined with Peginterferon alfa-2b.]
[C07AB02, metoprolol, The metabolism of Metoprolol can be decreased when combined with Peginterferon alfa-2b.]
[C01BB02, mexiletine, The serum concentration of Mexiletine can be increased when it is combined with Peginterferon alfa-2b.]
[N06AX03, mianserin, The serum concentration of Mianserin can be increased when it is combined with Peginterferon alfa-2b.]
[N02BB03, aminopyrine, The serum concentration of Aminophenazone can be increased when it is combined with Peginterferon alfa-2b.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Peginterferon alfa-2b.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Peginterferon alfa-2b.]
[C09CA03, valsartan, The metabolism of Valsartan can be increased when combined with Peginterferon alfa-2b.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mitoxantrone.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be decreased when combined with Peginterferon alfa-2b.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Peginterferon alfa-2b.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Peginterferon alfa-2b.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The serum concentration of Eltrombopag can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ofatumumab.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Peginterferon alfa-2b.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mycophenolic acid.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Peginterferon alfa-2b.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be increased when combined with Peginterferon alfa-2b.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon beta-1b.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Peginterferon alfa-2b.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ropinirole.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be decreased when combined with Peginterferon alfa-2b.]
[M02AA12, naproxen, The serum concentration of Naproxen can be increased when it is combined with Peginterferon alfa-2b.]
[A10BG01, troglitazone, The metabolism of Troglitazone can be increased when combined with Peginterferon alfa-2b.]
[N06AX21, duloxetine, The metabolism of Duloxetine can be decreased when combined with Peginterferon alfa-2b.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Peginterferon alfa-2b.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Docetaxel.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Peginterferon alfa-2b.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Peginterferon alfa-2b.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Amsacrine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Peginterferon alfa-2b.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be increased when combined with Peginterferon alfa-2b.]
[C08CA05, nifedipine, The serum concentration of Nifedipine can be increased when it is combined with Peginterferon alfa-2b.]
[C02KX01, bosentan, The metabolism of Bosentan can be increased when combined with Peginterferon alfa-2b.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Peginterferon alfa-2b.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon alfa-2b.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Peginterferon alfa-2b.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be increased when combined with Peginterferon alfa-2b.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Peginterferon alfa-2b.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon alfa-2b.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Peginterferon alfa-2b.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Peginterferon alfa-2b.]
[C07AA02, oxprenolol, The metabolism of Oxprenolol can be decreased when combined with Peginterferon alfa-2b.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Peginterferon alfa-2b.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Peginterferon alfa-2b.]
[N05AH05, asenapine, The serum concentration of Asenapine can be increased when it is combined with Peginterferon alfa-2b.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Peginterferon alfa-2b.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Paramethasone.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Peginterferon alfa-2b.]
[C07AA23, penbutolol, The metabolism of Penbutolol can be decreased when combined with Peginterferon alfa-2b.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Penicillamine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pentostatin.]
[C04AD03, pentoxifylline, The serum concentration of Pentoxifylline can be increased when it is combined with Peginterferon alfa-2b.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Peginterferon alfa-2b.]
[N05AB03, perphenazine, The serum concentration of Perphenazine can be increased when it is combined with Peginterferon alfa-2b.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Peginterferon alfa-2b.]
[N02BE03, phenacetin, The serum concentration of Phenacetin can be increased when it is combined with Peginterferon alfa-2b.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Peginterferon alfa-2b.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Peginterferon alfa-2b.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be increased when combined with Peginterferon alfa-2b.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be increased when combined with Peginterferon alfa-2b.]
[M02AA01, phenylbutazone, The metabolism of Phenylbutazone can be increased when combined with Peginterferon alfa-2b.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be increased when combined with Peginterferon alfa-2b.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Golimumab.]
[N05AG02, pimozide, The serum concentration of Pimozide can be increased when it is combined with Peginterferon alfa-2b.]
[C07AA03, pindolol, The metabolism of Pindolol can be decreased when combined with Peginterferon alfa-2b.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Peginterferon alfa-2b.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Peginterferon alfa-2b.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be increased when combined with Peginterferon alfa-2b.]
[J01MA11, grepafloxacin, The serum concentration of Grepafloxacin can be increased when it is combined with Peginterferon alfa-2b.]
[J05AG02, delavirdine, The metabolism of Delavirdine can be decreased when combined with Peginterferon alfa-2b.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be increased when combined with Peginterferon alfa-2b.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Peginterferon alfa-2b.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Peginterferon alfa-2b.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be increased when combined with Peginterferon alfa-2b.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfa-2b.]
[A03AE01, alosetron, The serum concentration of Alosetron can be increased when it is combined with Peginterferon alfa-2b.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Peginterferon alfa-2b.]
[J05AE03, ritonavir, The metabolism of Ritonavir can be decreased when combined with Peginterferon alfa-2b.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be increased when combined with Peginterferon alfa-2b.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Peginterferon alfa-2b.]
[P02BA01, praziquantel, The serum concentration of Praziquantel can be increased when it is combined with Peginterferon alfa-2b.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Prednisone.]
[P01BA03, primaquine, The serum concentration of Primaquine can be increased when it is combined with Peginterferon alfa-2b.]
[N03AA03, primidone, The metabolism of Primidone can be increased when combined with Peginterferon alfa-2b.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Peginterferon alfa-2b.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Procarbazine.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be decreased when combined with Peginterferon alfa-2b.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Peginterferon alfa-2b.]
[N05AA03, promazine, The serum concentration of Promazine can be increased when it is combined with Peginterferon alfa-2b.]
[R06AD02, promethazine, The metabolism of Promethazine can be decreased when combined with Peginterferon alfa-2b.]
[C01BC03, propafenone, The serum concentration of Propafenone can be increased when it is combined with Peginterferon alfa-2b.]
[N01AX10, propofol, The metabolism of Propofol can be increased when combined with Peginterferon alfa-2b.]
[N02AC04, propoxyphene, The metabolism of Dextropropoxyphene can be decreased when combined with Peginterferon alfa-2b.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Peginterferon alfa-2b.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Propylthiouracil.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Peginterferon alfa-2b.]
[R03DC03, montelukast, The metabolism of Montelukast can be increased when combined with Peginterferon alfa-2b.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Peginterferon alfa-2b.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Peginterferon alfa-2b.]
[P01BC01, quinine, The serum concentration of Quinine can be increased when it is combined with Peginterferon alfa-2b.]
[A02BA02, ranitidine, The serum concentration of Ranitidine can be increased when it is combined with Peginterferon alfa-2b.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be increased when combined with Peginterferon alfa-2b.]
[N04BD01, selegiline, The serum concentration of Selegiline can be increased when it is combined with Peginterferon alfa-2b.]
[C05BB02, polidocanol, The therapeutic efficacy of Polidocanol can be decreased when used in combination with Peginterferon alfa-2b.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Peginterferon alfa-2b.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Peginterferon alfa-2b.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Peginterferon alfa-2b.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be increased when combined with Peginterferon alfa-2b.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hydrocortisone butyrate.]
